95 results
Page 2 of 5
8-K
EX-99.1
vwmedq
8 Sep 22
InMed Pharmaceuticals Provides Update on its Core Research and Development Programs and BayMedica Business
4:02pm
8-K
EX-99.1
mn9gcjr2
26 Aug 22
InMed Announces Share Consolidation to Meet Nasdaq Listing Criteria
5:30pm
8-K
EX-99.1
6wo2go2
10 Aug 22
InMed Announces Changes to its Board of Directors
8:12pm
8-K
EX-99.1
i76f1u
26 Jul 22
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
1:32pm
8-K
EX-99.1
15wrue
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
424B3
nrif0rkb6 373y
6 Jul 22
Prospectus supplement
2:43pm
8-K
EX-99.1
5luz2d7 bwyy60
15 Jun 22
InMed Announces Publication of Peer-Reviewed Study Highlighting Potential
6:04pm
8-K
EX-99.1
sba9oc21s8rvfycu9s16
10 Jun 22
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
4:36pm
8-K
EX-99.1
qygzublp qrz2xas40
6 Jun 22
InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
9:47pm
8-K
EX-99.1
34f1g 5c43wp2
3 Jun 22
Entry into a Material Definitive Agreement
9:51pm
424B5
i9br fuikg
3 Jun 22
Prospectus supplement for primary offering
9:45pm
8-K
EX-99.1
c8z1 dokp
18 May 22
InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update
1:34pm
8-K
EX-99.1
rzy8kf2
6 May 22
Regulation FD Disclosure
2:50pm
8-K
EX-99.1
0jtk m0buqo
28 Apr 22
Regulation FD Disclosure
2:35pm
424B3
4sb7ys
25 Apr 22
Prospectus supplement
5:02pm
8-K
EX-99.1
49c c7djt
21 Apr 22
Regulation FD Disclosure
2:46pm
8-K
EX-99.1
ve8 tukcp435j
19 Apr 22
InMed to Participate in Upcoming Investor Conferences in April and May 2022
6:55pm
424B3
xawlpyd
7 Apr 22
Prospectus supplement
4:46pm